Arbutus Biopharma Corporation (ABUS)

[chmcnfunds]

One analyst sees the value:

"Tekmira (TKM:TSX, US$10.02, SPEC BUY, PT US$27.50)

returned T4W returns of -28%, likely still as a result of the news that the FDA had placed its TKM-Ebola trial on hold until revisions to the protocol were made to its existing protocol. The request came in light of an elevation in cytokine levels observed in some patients during the trial. We believe this is only a transient obstacle for the firm; although TKM-Ebola is currently developed specifically for US Government use but on a broader scale, the necessity for an Ebola-focused therapeutic is more critical than ever, with reports of serious outbreaks spreading in West Africa. And we remain positive on how TKM-Ebola’s now-published preclinical data reflects on siRNA potential in other viral diseases, including chronic hepatitis B for which IND filing by end-of-year is still expected and for which peer firms Arrowhead and Alnylam are advancing their own hepatitis B programs."

__________________________________

TKMR